natgillin/translations-raw huggingface dataset:
Additional caution should be exercised in patients who are prone to a disturbance of water or electrolyte balance (e.g. elderly, patients with cardiovascular (CV) diseases, diabetes, hypertension), and electrolyte control should be considered. 
Pri bolnikih, ki so nagnjeni k motnjam ravnovesja vode ali elektrolitov (tj. starostniki, bolniki z boleznimi srca in ožilja, sladkorno boleznijo, hipertenzijo) morate razmisliti o nadzorovanju elektrolitov.
The most frequently reported adverse reaction associated with Constella therapy was diarrhoea, mainly mild to moderate in intensity, occurring in less than 20% of patients. 
Neželeni učinek, o katerem so pri zdravljenju z zdravilom Constella najpogosteje poročali, je bila v glavnem blaga do zmerno huda driska, ki se je pojavila pri manj kot 20 % bolnikov.
Other signs and symptoms of IBS-C including bloating, complete spontaneous bowel movement (CSBM) frequency, straining, stool consistency, were improved in linaclotide treated patients vs. placebo (p<0.0001) as shown in the following table. 
Drugi znaki in simptomi sindroma razdražljivega črevesja z zaprtostjo, vključno z napenjanjem, pogostnostjo popolne spontane defekacije (CSBM - complete spontaneous bowel movement), naporom, konsistenco blata, so se izboljšali pri bolnikih, zdravljenih z linaklotidom v primerjavi s placebom (p<0,0001), kot je prikazano v spodnji tabeli.
In rare and more severe cases, this may - as a consequence - lead to the occurrence of dehydration, hypokalaemia, blood bicarbonate decrease, dizziness, and orthostatic hypotension. 
V redkih in hudih primerih lahko to povzroči dehidracijo, hipokaliemijo, znižane ravni hidrogenkarbonata v krvi, omotico in ortostatsko hipotenzijo.
In those patients in whom diarrhoea led to discontinuation, it resolved after a few days of discontinuing treatment. 
Pri teh bolnikih je driska izzvenela nekaj dni po prekinitvi zdravljenja.
Diarrhoea is normally short lived; however, if you experience severe or prolonged diarrhoea (passing frequent or watery stools for 7 days or more) and feel lightheaded, dizzy or faint, stop taking Constella and contact your doctor. 
Driska je običajno kratkotrajna, če pa se pojavi huda ali dolgotrajna driska (pogosto ali tekoče blato, ki traja 7 dni ali več) in imate občutek vrtoglavice, ste omotični ali omedlite, prenehajte jemati zdravilo Constella in se posvetujte s svojim zdravnikom.
Linaclotide has not been studied in patients with chronic inflammatory conditions of the intestinal tract, such as Crohn's disease and ulcerative colitis; therefore it is not recommended to use Constella in these patients. 
Linaklotida niso preučevali pri bolnikih s kroničnimi vnetnimi stanji prebavil, kot so Crohnova bolezen in ulcerozni kolitis, zato se uporaba zdravila Constella pri teh bolnikih ne priporoča.
Both linaclotide and des-tyrosine active metabolite are reduced and enzymatically proteolyzed within the gastrointestinal tract to smaller peptides and naturally occurring amino acids. 
Linaklotid in aktivni presnovek des-tirozin se v prebavilih reducirata in encimsko proteolizirata na manjše peptide in naravno prisotne aminokisline.
Effect of linaclotide on IBS-C symptoms during the first 12 weeks of treatment in the pooled phase 3 efficacy clinical studies (studies 1 and 2). 
Učinki linaklotida na simptome sindroma razdražljivega črevesja z zaprtostjo prvih 12 tednov zdravljenja v združenih študijah klinične učinkovitosti 3. faze (študiji 1 in 2).
How to store Constella 6. 
Shranjevanje zdravila Constella 6.
Concomitant treatment with proton pump inhibitors, laxatives or NSAIDs may increase the risk of diarrhoea. 
Sočasno zdravljenje z zaviralci protonske črpalke, odvajali ali nesteroidnimi protivnetnimi zdravili lahko poveča tveganje za drisko.
Extracellular cGMP decreases pain-fiber activity, resulting in reduced visceral pain in animal models. 
Zunajcelični cGMP zmanjša aktivnost bolečinskih vlaken, kar na živalskih modelih zmanjša visceralno bolečino.
Caution should be exercised when prescribing medicinal products absorbed in the intestinal tract with a narrow therapeutic index such as levothyroxine as their efficacy may be reduced. 
Pri predpisovanju zdravil, ki se absorbirajo v črevesje in imajo ozek terapevtski indeks, kot je levotiroksin, je potrebna previdnost, saj je lahko njihova učinkovitost zmanjšana.
Results of these studies showed that linaclotide and des-tyrosine metabolite are not inhibitors or inducers of the cytochrome P450 enzyme system. 
Rezultati teh študij so pokazali, da linaklotid in presnovek des-tirozin nista ne zaviralca ne induktorja encimskega sistema citokroma P450.
An IBS degree of relief responder was a patient that was considerably or completely relieved for at least 50% of the treatment period; an abdominal pain/discomfort responder was a patient that had an improvement of 30% or more for at least 50% of the treatment period. 
Odzivna oseba s stopnjo olajšanja sindroma razdražljivega črevesja pomeni bolnika z znatnim ali popolnim olajšanjem vsaj 50 odstotkov časa v obdobju zdravljenja, odzivna oseba z olajšanjem abdominalne bolečine/nelagodja pa je bil bolnik z vsaj 30-odstotnim izboljšanjem vsaj 50 odstotkov časa v obdobju zdravljenja.
Capsule content: microcrystalline cellulose, hypromellose, calcium chloride dihydrate and leucine. 
Vsebina kapsule: mikrokristalna celuloza, hipromeloza, kalcijev klorid dihidrat in levcin.
Some medicines may increase the risk of diarrhoea when taken with Constella, such as: - Medicines to treat stomach ulcers or excessive production of stomach acid called Proton Pump Inhibitors. 
Nekatera zdravila lahko povečajo tveganje za pojav driske ob hkratnem jemanju zdravila Constella, na primer: - zdravila za zdravljenje želodčnih razjed ali prekomernega tvorjenja želodčne kisline, imenovana zaviralci protonske črpalke; - zdravila za zdravljenje bolečine in vnetja, imenovana nesteroidna protivnetna zdravila (NSAID); - odvajala.
Pregnancy and breast-feeding Limited information is available on the effects of Constella in pregnant and breast-feeding women. 
Nosečnost in dojenje Podatki o uporabi zdravila Constella pri nosečnicah in doječih ženskah so omejeni.
In the two pivotal phase 3 studies in which patients were dosed with 290 micrograms of linaclotide once daily, linaclotide was only detected in 2 out of 162 patients approximately 2 h following the initial linaclotide dose (concentrations were 0.241 ng/ml to 0.239 ng/ml) and in none of the 162 patients after 4 weeks of treatment. 
V dveh ključnih študijah 3. faze, pri katerih so bolniki prejemali odmerek 290 mikrogramov linaklotida enkrat na dan, so linaklotid zaznali pri samo 2 od 162 bolnikov približno 2 uri po začetnem odmerku linaklotida (koncentracije so bile v razponu od 0,241 ng/ml do 0,239 ng/ml), in pri nobenem od 162 bolnikov po 4 tednih zdravljenja.
During the 2-weeks pre-treatment baseline period, patients had a mean abdominal pain score of 5.6 (0-10 scale) with 2.2% of abdominal pain-free days, a mean bloating score of 6.6 (0-10 scale), and an average of 1.8 spontaneous bowel movements (SBM)/week. 
Med 2-tedenskim izhodiščnim obdobjem pred zdravljenjem so imeli bolniki povprečni rezultat bolečine 5,6 (lestvica 0-10) z 2,2 % dneva brez bolečine v abdomnu, povprečnim rezultatom napenjanja 6,6 (lestvica 0-10) in 1,8 spontanimi defekacijami/teden.
Constella with food 
Zdravilo Constella skupaj s hrano
All patients met Rome II criteria for IBS-C and were required to report a mean abdominal pain score of ≥ 3 on a 0-to-10-point numeric rating scale (criteria that correspond to a moderate to severe IBS population), < 3 complete spontaneous bowel movements and ≤ 5 SBMs per week during a 2-week baseline period. 
Vsi bolniki so ustrezali merilom Rome II za sindrom razdražljivega črevesja z zaprtostjo in so morali imeti med 2-tedenskim izhodiščnim obdobjem povprečni rezultat abdominalnih bolečin ≥ 3 na numerični lestvici od 0 do 10 točk (kriterij, ki ustreza populaciji z zmernim do hudim simptomom razdražljivega črevesja), rezultat < 3 za popolno spontano defekacijo in ≤ 5 spontanih defekacij na teden.
PHARMACEUTICAL FORM AND CONTENTS Hard capsule. 
FARMACEVTSKA OBLIKA IN VSEBINA trda kapsula 28 kapsul.
Elderly (>65 years), hypertensive and diabetic patients reported diarrhoea more frequently as compared to the overall IBS-C population included in the clinical trials. 
Starostniki (> 65 let), bolniki s povišanim krvnim tlakom in bolniki s sladkorno boleznijo, so pogosteje poročali o driski kot splošna populacija bolnikov s sindromom razdražljivega črevesja z zaprtostjo, vključenih v klinična preskušanja.
What Constella is and what it is used for 
Kaj je zdravilo Constella in za kaj ga uporabljamo
INFORMATION IN BRAILLE constella 290 mcg 
constella 290 mcg
Diarrhoea is the most common adverse reaction and is consistent with the pharmacological action of the active substance. 
Driska je najpogostejši neželeni učinek in je v skladu s farmakološkim delovanjem zdravilne učinkovine.
Patients should be aware of the possible occurrence of diarrhoea and lower gastrointestinal bleeding during treatment. 
Bolniki morajo vedeti, da se lahko med zdravljenjem pojavi driska in krvavenje iz spodnjih prebavil.
The co-primary endpoints in both clinical studies were 12-week IBS degree of relief responder rate and 12 week abdominal pain/discomfort responder rate. 
Sočasna primarna opazovana dogodka v obeh kliničnih raziskavah sta bili delež odzivnih oseb s stopnjo olajšanja sindroma razdražljivega črevesja (IBS) pri 12 tednih in delež odzivnih oseb z olajšanjem abdominalnih bolečin/neugodja pri 12 tednih.
• urgency to pass stools 
• nujna potreba po odvajanju blata
Intracellular cGMP causes secretion of chloride and bicarbonate into the intestinal lumen, through activation of the cystic fibrosis transmembrane conductance regulator (CFTR), which results in increased intestinal fluid and accelerated transit. 
Znotrajcelični cGMP povzroči izločanje klorida in hidrogenkarbonata v črevesno svetlino z aktiviranjem transmembranskega regulatorja cistične fibroze (CFTR - cystic fibrosis transmembrane conductance regulator), kar poveča količino črevesne tekočine in pospeši prehod.
If you experience severe or prolonged diarrhoea (passing of frequent watery stools for 7 days or more), stop taking Constella and contact your doctor (see section 4). 
V primeru hude ali dolgotrajne driske (pogosto izločanje vodenega blata, ki traja 7 dni ali več) prenehajte jemati zdravilo Constella in se posvetujte s svojim zdravnikom (glejte poglavje 4).
No dose adjustments are required for patients with hepatic or renal impairment (see section 5.2). 
Odmerka za bolnike z okvaro jeter ali ledvic ni treba prilagajati (glejte poglavje 5.2).
2% of treated patients experienced severe diarrhoea and 5% of patients discontinued treatment due to diarrhoea in clinical studies. 
V kliničnih študijah je 2 % zdravljenih bolnikov imelo hudo drisko, 5 % bolnikov pa je zaradi driske prekinilo zdravljenje.
A food interaction clinical study in healthy subjects showed that linaclotide was not detectable in plasma either in fed or in fasted conditions at the therapeutic doses. 
Klinična študija interakcije s hrano pri zdravih osebah je pokazala, da linaklotida pri terapevtskih odmerkih ni bilo mogoče zaznati v plazmi na poln želodec ali na tešče.
Stool consistency (BSFS Score) 
Konsistenca blata (rezultat BSFS) Napor (5točkovna običajna lestvica)
Following a single oral dose of 2,897 micrograms linaclotide on day 8, after a 7-day course of 290 micrograms/day in 18 healthy volunteers, approximately 3 to 5% of the dose was recovered in the faeces, virtually all of it as the des-tyrosine active metabolite. 
Po enem peroralnem odmerku 2.897 mikrogramov na 8. dan po 7-dnevnem ciklu dajanja 290 mikrogramov/dan 18 zdravim prostovoljcem so v blatu zaznali približno 3 do 5 % odmerka, skoraj v celoti v obliki aktivnega presnovka des-tirozina.
Taking Constella immediately after a high fat breakfast resulted in more frequent and looser stools, as well as more gastrointestinal adverse events, compared with taking it in the fasted state. 
Jemanje zdravila Constella neposredno po zajtrku z visoko vsebnostjo maščob je povzročilo pogostejše odvajanje in redkejše blato ter več neželenih učinkov na črevesje, v primerjavi z jemanjem na tešče.
Linaclotide has been given orally to 1,166 patients with IBS-C in controlled clinical studies. 
Linaklotid je bil dajan peroralno 1.166 bolnikom s sindromom razdražljivega črevesja z zaprtostjo v kontroliranih kliničnih študijah.
It is preferable to discuss stopping treatment with your doctor before actually doing so. 
Najbolje je, da se pred dejanskim prenehanjem jemanja zdravila Constella o tem pogovorite s svojim zdravnikom.
Patients with known or suspected mechanical gastrointestinal obstruction. 
Bolniki z znano mehanično obstrukcijo prebavil ali s sumom nanjo.
If you stop taking Constella 
Če ste prenehali jemati zdravilo Constella
Linaclotide is rarely detectable in plasma following administration of the recommended clinical doses and in vitro studies have shown that linaclotide is neither a substrate nor an inhibitor/inducer of the cytochrome P450 enzyme system and does not interact with a series of common efflux and uptake transporters (see section 5.2). 
Po uporabi priporočenega kliničnega odmerka se linaklotid v plazmi redko zazna, študije in vitro pa so pokazale, da linaklotid ni niti substrat niti inhibitor/induktor encimskega sistema citokroma P450 in ne stopa v interakcijo z vrsto običajnih izločevalnih in privzemnih prenašalcev (glejte poglavje 5.2).
Both linaclotide and its active metabolite bind to the GC-C receptor, on the luminal surface of the intestinal epithelium. 
Linaklotid in njegov aktivni presnovek se vežeta na receptor GC-C na površini svetline črevesnega epitelija.
When 2,897 micrograms was administered on day 8, following a 7-day course of 290 micrograms/day, linaclotide was detectable in only 2 of 18 subjects at concentrations just above the lower limit of quantification of 0.2 ng/ml (concentrations ranged from 0.212 to 0.735 ng/ml). 
Po odmerku 2.897 mikrogramov na 8. dan, ki je sledil 7-dnevnem ciklu uporabe 290 mikrogramov/dan, so linaklotid zaznali pri samo 2 od 18 oseb v koncentracijah, ki so malo nad mejo določljivosti, in je 0,2 ng/ml (koncentracije so bile v razponu od 0,212 do 0,735 ng/ml).
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential and toxicity to reproduction and development. 
Predklinični podatki na osnovi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih odmerkih, genotoksičnosti, kancerogenega potenciala, vpliva na sposobnost razmnoževanja in razvoja ne kažejo posebnega tveganja za človeka.
Constella is indicated for the symptomatic treatment of moderate to severe irritable bowel syndrome with constipation (IBS-C) in adults. 
Zdravilo Constella je indicirano pri odraslih za simptomatsko zdravljenje srednje hudega do hudega sindroma razdražljivega črevesja z zaprtostjo (IBS-C - irritable bowel syndrome with constipation).
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION 
DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA TRGOVANJE Z ZDRAVILOM
Warning: The bottle contains one or more sealed canisters containing silica gel to keep the capsules dry. 
Opozorilo: Plastenka vsebuje eno ali več zatesnjenih vsebnikov s silikagelom, ki ohranja kapsule suhe.
• wind 
• vetrovi
Linaclotide is rarely detectable in plasma, therefore, renal impairment would not be expected to affect clearance of the parent compound or its metabolite. 
Linaklotid je v plazmi le redko zaznaven, zato ni pričakovati, da bi okvarjeno delovanje ledvic vplivalo na očistek prvotne spojine ali njenega presnovka.
Orthostatic hypotension 
Žilne bolezni ortostatska hipotenzija
The efficacy of linaclotide was established in two randomised, double-blind, placebo-controlled Phase 3 clinical studies in patients with IBS-C. 
Učinkovitost linaklotida je bila ugotovljena v dveh randomiziranih, dvojno slepih, s placebom kontroliranih kliničnih študijah 3. faze pri bolnikih s sindromom razdražljivega črevesja z zaprtostjo.
What Constella is used for 
Za kaj se zdravilo Constella uporablja
In a cross-over food interaction study, 18 healthy subjects were administered Constella 290 micrograms for 7 days both in the fasting and fed state. 
Pri navzkrižni študiji interakcij s hrano so 18 zdravim osebam 7 dni dajali zdravilo Constella 290 mikrogramov na poln želodec in na tešče.
Constella acts locally in your gut, helping you to feel less pain and less bloated, and to restore the normal functioning of your bowels. 
Zdravilo Constella deluje lokalno v črevesju tako, da zmanjša občutek bolečine in napenjanje ter ponovno vzpostavi običajno delovanje črevesja.
Straining (5-point ordinal scale) *p<0.0001, linaclotide vs placebo. 
*p < 0,0001, linaklotid v primerjavi s placebom.
Activation of GC-C results in an increase in concentrations of cyclic guanosine monophosphate (cGMP), both extracellularly and intracellularly. 
Aktiviranje GC-C povzroči povečanje zunajceličnih in znotrajceličnih koncentracij cikličnega gvanozin monofosfata (cGMP).
Five percent of patients discontinued treatment due to diarrhoea in clinical studies. 
Pri kliničnih preskušanjih je pet odstotkov bolnikov prekinilo zdravljenje zaradi driske.
White to off-white-orange opaque capsule (18 mm x 6.35 mm) marked “290” with grey ink. 
FARMACEVTSKA OBLIKA trda kapsula bela do belkasta in oranžna neprozorna kapsula (18 mm x 6,35 mm) z oznako „290“ v sivem črnilu
Hypokalaemia Dehydration Decreased appetite 
Presnovne in prehranske motnje hipokaliemija, dehidracija, zmanjšan apetit
Constella is available in packs containing 10, 28 or 90 capsules and in multipacks of 112 capsules comprising 4 cartons, each containing 28 capsules. 
Zdravilo Constella je na voljo v pakiranjih, ki vsebujejo po 10, 28 ali 90 kapsul, in v velikih pakiranjih s 112 kapsulami, ki vsebujejo 4 plastenke s po 28 kapsulami.
Driving and using machines Constella will not affect your ability to drive or use machines 
Vpliv na sposobnost upravljanja vozil in strojev Zdravilo Constella ne vpliva na sposobnost vožnje in upravljanja s stroji.
Constella should be used after organic diseases have been ruled out and a diagnosis of moderate to severe IBS-C (see section 5.1) is established. 
Zdravilo Constella uporabite po izključitvi organskih bolezni in po postavitvi diagnoze zmerno hudega do hudega razdražljivega črevesja z zaprtjem (glejte poglavje 5.1).
Constella contains the active substance linaclotide. 
Zdravilo Constella vsebuje zdravilno učinkovino linaklotid.
Caution should be used when co-administering Constella with such medications. 
Pri sočasni uporabi zdravila Constella in tovrstnih zdravil je potrebna previdnost.
It is used to treat the symptoms of moderate to severe irritable bowel syndrome (often just called “IBS”) with constipation in adult patients. 
Uporablja se za zdravljenje zmerno hudih do hudih simptomov razdražljivega črevesja (IBS - irritable bowel syndrome) z zaprtostjo pri odraslih bolnikih.
UNIQUE IDENTIFIER - 2D BARCODE 2D barcode carrying the unique identifier included. 
2D črtna koda z enolično identifikacijsko oznako je priložena.
The bottle contains one or more sealed canisters containing silica gel to keep the capsules dry. 
Plastenka vsebuje eno ali več zatesnjenih vsebnikov s silikagelom, ki ohranja kapsule suhe.
• stomach or abdominal pain 
• bolečina v želodcu ali trebuhu
- If you have any further questions, ask your doctor or pharmacist. 
- Če imate dodatna vprašanja, se posvetujte s svojim zdravnikom ali farmacevtom.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING INNER CARTON CONTAINING SINGLE 28 CAPSULE BOTTLES (MULTIPACK) WITHOUT BLUE BOX 
NOTRANJA ŠKATLA Z ENO PLASTENKO Z 28 KAPSULAMI (VELIKO PAKIRANJE) BREZ "BLUE BOX" PODATKOV
Taking Constella in the fed condition produced more frequent and looser stools, as well as more gastrointestinal adverse events, than when taking it under fasting conditions (see section 5.1). 
Jemanje zdravila Constella na poln želodec je povzročilo pogostejše odvajanje in bolj mehko blato ter več neželenih učinkov na črevesje kot pri jemanju na tešče (glejte poglavje 5.1).
Each capsule contains 290 micrograms of linaclotide. 
Ena kapsula vsebuje 290 mikrogramov linaklotida.
Linaclotide is metabolised locally within the gastrointestinal tract to its active primary metabolite, destyrosine. 
Linaklotid se v prebavilih lokalno presnovi do svojega aktivnega primarnega presnovka, des-tirozina.
Constella produces more frequent bowel movements and diarrhoea (looser stools) when it is taken with food than when it is taken on an empty stomach (see section 3). 
Zdravilo Constella lahko pri jemanju skupaj s hrano povzroči pogostejšo potrebo po iztrebljanju ali drisko (tekoče blato), kot če ga jemljete na prazen želodec (glejte poglavje 3).
Through its action at GC-C, linaclotide has been shown to reduce visceral pain and increase GI transit in animal models and increase colonic transit in humans. 
Na živalskih modelih so dokazali, da delovanje linaklotida na GC-C zmanjša visceralne bolečine in poveča prehod skozi prebavila, pri ljudeh pa poveča prehod skozi debelo črevo.
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
IZDELOVALEC, ODGOVOREN ZA SPROŠČANJE SERIJE
Capsule shell: red iron oxide (E172), titanium dioxide (E171), yellow iron oxide (E172) and gelatin. 
Ovojnica kapsule: rdeči železov oksid (E172), titanov dioksid (E171), rumeni železov oksid (E172) in želatina.
• infrequent, hard, small or pellet-like stools (faeces). 
• neredno odvajanje blata, trdo, majhno ali v kroglice oblikovano blato
White high density polyethylene (HDPE) bottle with a tamper evident seal and a child-resistant closure, together with one or more desiccant canisters containing silica gel. 
Bela plastenka iz polietilena velike gostote (HDPE) s pečatom proti poseganju, z za otroke varnim pokrovčkom, skupaj z enim ali več vsebniki silikagela kot sredstva za sušenje.
Marketing Authorisation Holder Allergan Pharmaceuticals International Limited Clonshaugh Business & Technology Park Dublin 17, D17 E400 
Imetnik dovoljenja za promet z zdravilom Allergan Pharmaceuticals International Limited Clonshaugh Business & Technology Park Dublin 17, D17 E400
Pack sizes: 10, 28 or 90 capsules and multipacks containing 112 (4 packs of 28) capsules. 
Velikosti pakiranja: 10, 28 ali 90 kapsul ter večkratna pakiranja s 112 (4 pakiranja po 28) kapsulami.
Linaclotide is rarely detectable in plasma and is not metabolised by liver cytochrome P450 enzymes, therefore, hepatic impairment would not be expected to affect the metabolism or clearance of the parent drug or its metabolite. 
Linaklotid je v plazmi le redko zaznaven, encimi jetrnega citokromskega sistema P450 pa ga ne presnavljajo, zato ni pričakovati, da bi okvara jeter vplivala na presnovo ali očistek prvotnega zdravila ali njegovega presnovka.
• bicarbonate decrease in your blood 
• znižana raven hidrogenkarbonata v krvi
Printing ink: shellac, propylene glycol, concentrated ammonia solution, potassium hydroxide, titanium dioxide (E171) and black iron oxide (E172). 
Črnilo: šelak, propilenglikol, koncentrirana raztopina amoniaka, kalijev hidroksid, titanov dioksid (E171) in črni železov oksid (E172).
They are packaged in a white, high density polyethylene (HDPE) bottle with a tamper evident seal and a child-resistant screw cap, together with one or more desiccant canisters containing silica gel. 
Pakirane so v beli plastenki iz polietilena velike gostote (HDPE) s pečatom proti poseganju in za otroke varno navojno zaporko, skupaj z enim ali več vsebniki silikagela kot sredstva za sušenje.
How to store Constella 
Kako jemati zdravilo Constella
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON CONTAINING 4 x 28 CAPSULE BOTTLES (MULTIPACK) WITH BLUE BOX 
ZUNANJA ŠKATLA S 4 PLASTENKAMI S PO 28 KAPSULAMI (VEČKRATNO PAKIRANJE) VKLJUČNO Z "BLUE BOX" PODATKI
EU/1/12/801/001 10 capsules EU/1/12/801/002 28 capsules EU/1/12/801/004 90 capsules 
EU/1/12/801/001 10 kapsul EU/1/12/801/002 28 kapsul EU/1/12/801/004 90 kapsul
Constella 290 micrograms hard capsules linaclotide 
Constella 290 mikrogramov trde kapsule linaklotid